These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 1659363)

  • 1. Humoral immune responses to inactivated oil-emulsified Marek's disease vaccine.
    Lee LF; Witter RL
    Avian Dis; 1991; 35(3):452-9. PubMed ID: 1659363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody titers to infectious bursal disease virus in broiler chicks after vaccination at one day of age with infectious bursal disease virus and Marek's disease virus.
    Knoblich HV; Sommer SE; Jackwood DJ
    Avian Dis; 2000; 44(4):874-84. PubMed ID: 11195642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of chickens against very virulent infectious bursal disease virus (IBDV) and Marek's disease virus (MDV) with a recombinant MDV expressing IBDV VP2.
    Tsukamoto K; Kojima C; Komori Y; Tanimura N; Mase M; Yamaguchi S
    Virology; 1999 May; 257(2):352-62. PubMed ID: 10329546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early posthatch protection against Marek's disease in chickens vaccinated in ovo with a CVI988 serotype 1 vaccine.
    Zhang Y; Sharma JM
    Avian Dis; 2001; 45(3):639-45. PubMed ID: 11569737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a bivalent vaccine against Marek's disease.
    Pruthi AK; Gupta RK; Sadana JR
    Res Vet Sci; 1987 Mar; 42(2):145-9. PubMed ID: 3035660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Difference between influences of homologous and heterologous maternal antibodies on response to serotype-2 and serotype-3 Marek's disease vaccines.
    King D; Page D; Schat KA; Calnek BW
    Avian Dis; 1981; 25(1):74-81. PubMed ID: 6268052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuated revertant serotype 1 Marek's disease viruses: safety and protective efficacy.
    Witter RL
    Avian Dis; 1991; 35(4):877-91. PubMed ID: 1664721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between the immunosuppressive potential and the pathotype of Marek's disease virus isolates.
    Calnek BW; Harris RW; Buscaglia C; Schat KA; Lucio B
    Avian Dis; 1998; 42(1):124-32. PubMed ID: 9533089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Derivation, safety and efficacy of a Marek's disease vaccine developed from an Australian isolate of very virulent Marek's disease virus.
    Karpathy RC; Firth GA; Tannock GA
    Aust Vet J; 2002; 80(1-2):61-6. PubMed ID: 12180882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of maternal antibody on efficacy of embryo vaccination with cell-associated and cell-free Marek's disease vaccine.
    Sharma JM; Graham CK
    Avian Dis; 1982; 26(4):860-70. PubMed ID: 6297450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a combination vaccine containing MDV CVI 988 strain and HVT against challenge with very virulent MDV.
    Geerligs HJ; Weststrate MW; Pertile TL; Rodenberg J; Kumar M; Chu S
    Acta Virol; 1999; 43(2-3):198-200. PubMed ID: 10696445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotype specificity of B-haplotype influence on the relative efficacy of Marek's disease vaccines.
    Bacon LD; Witter RL
    Avian Dis; 1994; 38(1):65-71. PubMed ID: 8002902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of cell-free or cell-associated turkey herpesvirus vaccine against Marek's disease in chickens as influenced by maternal antibody, vaccine dose, and time of exposure to Marek's disease virus.
    Eidson CS; Page RK; Kleven SH
    Avian Dis; 1978; 22(4):583-97. PubMed ID: 219826
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of infectious bursal disease virus on protection against Marek's disease by turkey herpesvirus vaccine.
    Sharma JM
    Avian Dis; 1984; 28(3):629-40. PubMed ID: 6091603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy in chickens of a herpesvirus of turkeys recombinant vaccine containing the fusion gene of Newcastle disease virus: onset of protection and effect of maternal antibodies.
    Morgan RW; Gelb J; Pope CR; Sondermeijer PJ
    Avian Dis; 1993; 37(4):1032-40. PubMed ID: 8141730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duration of vaccinal immunity against Marek's disease.
    Witter RL; Offenbecker L
    Avian Dis; 1978; 22(3):396-408. PubMed ID: 211999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Properties of a meq-deleted rmd5 Marek's disease vaccine: protection against virulent MDV challenge and induction of lymphoid organ atrophy are simultaneously attenuated by serial passage in vitro.
    Lee LF; Kreager K; Heidari M; Zhang H; Lupiani B; Reddy SM; Fadly A
    Avian Dis; 2013 Jun; 57(2 Suppl):491-7. PubMed ID: 23901766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoglobulins and anti-Marek's disease virus antibody synthesis in chickens after passive immunization with immunoglobulin Y anti-Marek's disease virus antibody.
    Kermani-Arab V; Moll T; Davis WC; Cho BR; Lu YS; Leslie GA
    Am J Vet Res; 1975 Nov; 36(11):1655-61. PubMed ID: 171985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial protection against Marek's disease in chickens immunized with glycoproteins gB purified from turkey-herpesvirus-infected cells by affinity chromatography coupled with monoclonal antibodies.
    Ono K; Takashima M; Ishikawa T; Hayashi M; Yoshida I; Konobe T; Ikuta K; Nakajima K; Ueda S; Kato S
    Avian Dis; 1985; 29(2):533-9. PubMed ID: 3896223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of maternal immunity against development of Marek's disease and protective ability of vaccine.
    Yoshida I; Yuasa N; Horiuchi T; Tsubahara H
    Natl Inst Anim Health Q (Tokyo); 1975; 15(1):1-7. PubMed ID: 804667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.